Phase 2 Study of SAR302503 in Patients With Myelofibrosis
NCT01420770
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Hematopoietic Neoplasm
Interventions
DRUG:
SAR302503
Sponsor
Bristol-Myers Squibb